Charles River Labs Files 8-K on Financial Obligation
Ticker: CRL · Form: 8-K · Filed: Dec 13, 2024 · CIK: 1100682
Sentiment: neutral
Topics: debt, financial-obligation
Related Tickers: CRL
TL;DR
CRL just filed an 8-K about a new financial obligation. Details TBD.
AI Summary
Charles River Laboratories International, Inc. filed an 8-K on December 13, 2024, reporting the creation of a direct financial obligation. The filing does not specify the exact nature or amount of the obligation, but it falls under Item Information related to financial statements and exhibits.
Why It Matters
This filing indicates a new financial commitment or debt for Charles River Laboratories, which could impact its financial structure and future obligations.
Risk Assessment
Risk Level: medium — The filing indicates a new financial obligation, which could carry inherent risks depending on its terms and the company's ability to manage it.
Key Players & Entities
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (company) — Registrant
- 0000950103-24-017767 (filing_id) — Accession Number
- December 13, 2024 (date) — Report Date
FAQ
What is the specific nature of the direct financial obligation reported by Charles River Laboratories?
The 8-K filing does not specify the exact nature of the direct financial obligation, only that one has been created.
What is the amount of the financial obligation?
The filing does not disclose the specific dollar amount of the financial obligation.
When was this financial obligation created or reported?
The obligation was reported on December 13, 2024, as the date of the earliest event reported.
Under which SEC filing item is this obligation reported?
This is reported under Item Information concerning the Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
Does this filing provide details on any off-balance sheet arrangements?
The filing mentions 'Obligation under an Off-Balance Sheet Arrangement' as a category of Item Information, but does not provide specific details about any such arrangements in the provided text.
Filing Stats: 906 words · 4 min read · ~3 pages · Grade level 12.7 · Accepted 2024-12-13 16:42:51
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value CRL New York Stock Exchange
- $3 billion — e revolving commitments thereunder from $3 billion to $2 billion, (3) incorporates Charles
- $2 b — mmitments thereunder from $3 billion to $2 billion, (3) incorporates Charles River L
- $2 billion — eement provides for up to approximately $2 billion in financing pursuant to a revolving cr
Filing Documents
- dp222024_8k.htm (8-K) — 36KB
- dp222024_ex1001.htm (EX-10.1) — 979KB
- 0000950103-24-017767.txt ( ) — 1387KB
- crl-20241213.xsd (EX-101.SCH) — 3KB
- crl-20241213_lab.xml (EX-101.LAB) — 33KB
- crl-20241213_pre.xml (EX-101.PRE) — 22KB
- dp222024_8k_htm.xml (XML) — 3KB
03
ITEM 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On December 13, 2024, Charles River Laboratories International, Inc. ("Charles River") amended and restated its existing credit agreement with certain financial institutions and JPMorgan Chase Bank, N.A., as administrative agent (the "Tenth Amended and Restated Credit Agreement"). The Tenth Amended and Restated Credit Agreement (1) extends the maturity date for the facilities, (2) reduces the aggregate revolving commitments thereunder from $3 billion to $2 billion, (3) incorporates Charles River Laboratories, Inc. ("CRL"), a direct subsidiary of Charles River, as a borrower under the credit agreement and (4) makes certain other amendments to certain other covenants and terms. Subject to certain customary exceptions, the obligations of Charles River under the Tenth Amended and Restated Credit Agreement are guaranteed by CRL, and are secured by substantially all of the assets of Charles River, CRL and any future material domestic subsidiaries of Charles River, including a pledge of 100% of the capital stock of CRL and any future material domestic subsidiaries of Charles River, and 65% of the capital stock of certain first-tier material foreign subsidiaries of Charles River and the guarantors. The Tenth Amended and Restated Credit Agreement provides for up to approximately $2 billion in financing pursuant to a revolving credit facility. The revolving facility is available in U.S. dollars to Charles River and CRL and in euros and sterling to Charles River and certain of its subsidiaries based in the United Kingdom, the Netherlands and Luxembourg (the "Multicurrency Revolving Facility"). The revolving facility matures on December 13, 2029, and requires no scheduled payment before that date. The interest rates applicable to revolving loans under the credit agreement are equal to (A) for revolving loans denominated in U.S. dollars, at Charles Riv
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. 10.1 Tenth Amended and Restated Credit Agreement, dated as of December 13, 2024, among Charles River Laboratories International, Inc., the Subsidiary Borrowers party thereto, the lenders party thereto, JPMorgan Chase Bank, N.A. as administrative agent, and the other agents party thereto. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: December 13, 2024 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Registrant) By: /s/ Madeline Moore Name: Madeline Moore Title: Assistant Secretary